A Fast, Quiet, Artificial Intelligence-based PET/MR Solution for Paediatric Diseases
- Conditions
- Paediatric Patients
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06709690
- Locations
- 🇨🇳
China, Shanghai Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine, Shanghai, Shanghai, China
Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 3000
- Registration Number
- NCT06708130
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Shanghai Liquan Hospital, Shanghai, China
🇨🇳Shanghai Zhaxin Hospital, Shanghai, China
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONDiabetes MellitusImpaired Fasting Glucose
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT06704542
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Wuhan, Hubei, China
🇨🇳Li Quan Hospital, Shanghai, Shanghai, China
Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients
- Conditions
- Enteropathy Associated T Cell Lymphoma
- Interventions
- Drug: Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 7
- Registration Number
- NCT06701344
CR-CHOP+X in Previously Untreated DEL
- Conditions
- DLBCL
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT06701357
- Locations
- 🇨🇳
No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai, Shanghai, China
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT06697366
The Effect of Physical Activity Level Evaluated by Wrist-wearable Devices on Cardiovascular Disease Risk and Other Outcomes in Peritoneal Dialysis Patients
- Conditions
- Peritoneal DialysisCardiovascular DiseasesMyocardial InfarctHeart FailureCognitive Disorders
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 266
- Registration Number
- NCT06697418
- Locations
- 🇨🇳
Ruijin Hospital - Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
- Conditions
- B-NHLCART Therapy
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT06695013
- Locations
- 🇨🇳
Ruijin, Shanghai, Shanghai, China
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses
- Conditions
- Severe Viral Pneumonia(Not Include COVID-19)
- Interventions
- Drug: PlaceboDrug: Drug therapyOther: Standard Treatment
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06693362
- Locations
- 🇨🇳
Ruijin Hospital affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai, China
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
- Conditions
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06693128
- Locations
- 🇨🇳
Sichuan Cancer Hospital & Institute, Chengdu, China
🇨🇳Changhai Hospital, Shanghai, China
🇨🇳Yantai Yuhuangding Hospital, Yantai, China